GlassScriptPhysician profile
Chi Q Duong
NPI 1285642108
$4,094.56
in general payments reported to CMS, 2019-2025
32 companies · $2,602 in 2025
The $2,602 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.23 · 2021: $487 · 2022: $472 · 2023: $192 · 2024: $295 · 2025: $2,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,088.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $998.06 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $509.01 | 2021-2025 | |
| Edwards Lifesciences Corporation | $341.88 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amgen INC. | $323.83 | 2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $244.07 | 2025 | |
| Lilly USA, LLC | $241.32 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $194.34 | 2025 | Ozempic, Rybelsus, Wegovy |
| Eisai INC. | $193.40 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.33 | 2021-2025 | Ofev, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.84 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $112.20 | 2025 | Trelegy Ellipta |
| Abbott Laboratories | $97.10 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Intra-Sana Laboratories | $51.29 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Coloplast Corp | $47.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.35 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $39.27 | 2025 | |
| Sumitomo Pharma America, INC. | $37.32 | 2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $36.14 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $35.48 | 2021 | |
| Acerus Pharmaceuticals Corporation | $34.84 | 2021-2022 | |
| Irhythm Technologies, INC. | $24.94 | 2022 | |
| Abiomed | $23.41 | 2023 | Impella |
| Merck Sharp & Dohme LLC | $21.78 | 2025 | Zerbaxa |
| Exact Sciences Corporation | $20.81 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $19.35 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.89 | 2025 | Spravato |
| Viiv Healthcare Company | $18.56 | 2022 | |
| Averitas Pharma INC. | $18.12 | 2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.74 | 2025 | Xifaxan |
| Verity Pharmaceuticals INC. | $16.40 | 2025 | Tlando |
| Inspire Medical Systems, INC. | $15.71 | 2025 | Inspire |
| Corcept Therapeutics | $15.55 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chi Duong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.